跳至主要内容
临床试验/NCT01268813
NCT01268813Unknown1 期

Personalized Medicine in Diabetes Using a Nanotechnology Platform

Rambam Health Care Campus2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2011年2月最近更新:
适应症

试验速览

阶段
1 期
入组人数
60
试验地点
2
主要终点
Development of Diabetes or complication

研究概览

简要总结

The metabolic syndrome is a collection of related risk factors that predispose to the development of type 2 diabetes Mellitus and cardiovascular disease. The investigators will examine the hypothesis that the metabolic and genomic characteristics of patients with metabolic syndrome and/or diabetes that are at risk for developing complications differ from each other and can be detected using specific biomarkers in blood or in the exhaled breath. Early detection of these individuals will enable personalized treatment to prevent and treat diabetes and its complications

详细描述

Breath samples will be collected in inert respiratory bag from diabetic and healthy volunteers, and analyzed using a chamber containing nano-chemical sensors. These samples together with blood samples will additionally be characterized using Gas Chromatography-Mass Spectroscopy "GC-MS".

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Metabolic Syndrome
  • Type 2 diabetes
  • Healthy volunteers with 20<Body Mass Index<25

排除标准

  • Chronic or acute lung disease

结局指标

主要结局

Development of Diabetes or complication

时间窗: 2 years

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验